What Mwyngil Therapeutics does

Mwyngil Therapeutics is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in San Diego (with affiliated operations in Dover, Delaware and Boston, Massachusetts, plus research ties to Europe via DZNE). The company develops oral small-molecule therapies for metabolic, inflammatory, neuroinflammatory, and renal diseases, with five named pipeline candidates across three mechanism classes: GPR75 inverse agonists (MW-401), NLRP3 inflammasome inhibitors (MW-504, MW-313, and BT-409), and PTP1B inhibitors (MW-601). Target indications include obesity and cardiometabolic disease, chronic kidney disease, cardiovascular disease, multiple sclerosis, and Parkinson's disease, with the lead asset (BT-409) having entered Phase 1 in February 2026 and the GPR75 program generating positive in vivo proof-of-concept data in June 2026.

The company's discovery engine combines two platforms: an AI/ML-enabled R&D platform licensed from Expert Systems Inc. that guides target selection and molecule design, and an internal Biological Research Platform that integrates human-relevant in vitro/ex vivo systems with in vivo disease models. Strategic differentiation rests on strong human genetics validation for GPR75 (loss-of-function variants from a ~640,000-individual study) and on candidate attributes such as up to 25% body weight reduction with preserved lean mass in DIO models, brain-permeable NLRP3 inhibition for CNS indications, and oral bioavailability compatible with once-daily dosing.

Mwyngil operates as a privately held, venture-backed entity with no commercialized products and no disclosed revenue. The company is seed-funded by OrbiMed and Torrey Pines Investment, both of which maintain board representation (Carl Gordon as Chairman; Iain Dukes as Venture Partner), with founding scientific collaboration from DZNE. Its go-to-market model relies on out-licensing partnered assets — BT-409 to Brenig Therapeutics for neuroinflammatory indications — while retaining wholly owned programs targeting obesity and CKD. Distribution is therefore not yet a commercial function; future commercialization is expected to involve additional licensing, co-development, or partnership-based routes rather than direct sales infrastructure.

Name

Mwyngil Therapeutics

Legal name

Mwyngil Therapeutics Inc.

Website

https://mwyngil.com

Company type

Private

Founded year

2021

Operating status

Operating

Short description

Mwyngil Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies targeting GPR75, NLRP3, and PTP1B for obesity, chronic kidney disease, and neuroinflammatory disorders, supported by an AI/ML-enabled discovery platform.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels2 records

Marketing channels5 records

Core offering

Mwyngil Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops oral small-molecule therapies targeting metabolic, inflammatory, neuroinflammatory, and renal diseases. The company leverages proprietary AI/ML-enabled drug discovery and biological research platforms to advance a pipeline of five candidates (MW-601, MW-504, MW-313, MW-401, BT-409) toward and through Phase 1 clinical development.

Product overview

Mwyngil Therapeutics is a clinical-stage biotechnology company developing a portfolio of first-in-class and best-in-class oral small-molecule therapies for obesity, chronic kidney disease (CKD), cardiometabolic disorders, and neuroinflammatory diseases. Its pipeline comprises five named clinical and preclinical candidates targeting distinct mechanisms: MW-601 (PTP1B inhibitor) for obesity via hypothalamic resensitization; MW-504 (NLRP3 inhibitor) for obesity-driven metabolic inflammation; MW-313 (systemic NLRP3 inhibitor) for CKD and cardiovascular disease; MW-401 (GPR75 inverse agonist) for obesity via central metabolic rebalancing; and BT-409 (brain-permeable NLRP3 inhibitor) partnered to Brenig Therapeutics for MS and Parkinson's disease. These programs are supported by two internal platforms: an AI/ML-enabled R&D platform (licensed from Expert Systems Inc.) that guides target selection and molecule design, and a Biological Research Platform providing human-relevant in vitro/ex vivo and in vivo disease models.

Differentiator

Problem solved

Functional benefit

Products and services

• MW-601

Quantifiable outcome

• Up to 25% body weight reduction with preserved lean mass in diet-induced obesity mouse models over 4 weeks
• +4 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and foundational.

• Expert Systems Inc.coreTechnology or Integration · 6 November 2025In-licensed GPR75 modulator molecules and proprietary cell-surface discovery platform from Expert Systems Inc. Collaboration combines Expert Systems' AI/ML-enabled drug discovery capabilities with Mwyngil's brain-permeable and systemic NLRP3 inhibitor programs to address intertwined metabolic and inflammatory disease pathways.
• Brenig TherapeuticscoreStrategic or Co-development Partner · 1 January 2025Partnered BT-409 (brain-permeable NLRP3 inhibitor) to Brenig Therapeutics for development in Parkinson's disease and other neuroinflammatory indications. BT-409 represents the first clinical-stage asset originating from Mwyngil's platform. Brenig is responsible for Phase 1 clinical execution.
• DZNE (Deutsche Zentrum für Neurodegenerative Erkrankungen)foundationalStrategic or Co-development Partner · 1 January 2021German research institution (German Center for Neurodegenerative Diseases) that collaborated with Torrey Pines to found Mwyngil Therapeutics. Scientific collaboration providing foundational scientific expertise in neuroinflammatory and neurodegenerative disease research.

Recent moves6 records

Expansion highlights6 records

Direct peers

• Rivus Pharmaceuticals: Clinical-stage biopharmaceutical company developing controlled metabolic accelerators (HU6) for cardiometabolic disease. Comparable to Mwyngil's cardiometabolic disease focus and lean-mass-preserving weight-loss mechanism.
• Nodthera: Private UK-based clinical-stage biopharmaceutical company developing selective NLRP3 inflammasome inhibitors for inflammatory and metabolic diseases. The most directly comparable peer to Mwyngil's NLRP3 portfolio, sharing target and disease focus.
• BioAge Labs: Clinical-stage biopharmaceutical company developing small-molecule therapies for metabolic disease (azelaprag) leveraging aging biology insights. Comparable to Mwyngil as a peer-stage metabolic small-molecule biotech.
• Structure Therapeutics: Clinical-stage biopharmaceutical company developing oral small-molecule GLP-1 receptor agonists for obesity and cardiometabolic disease. Comparable to Mwyngil as both pursue differentiated oral small-molecule therapies for obesity and metabolic disease in similar development stages.
• Akero Therapeutics: Clinical-stage biopharmaceutical company developing efruxifermin (FGF21 analog) for MASH/NASH and metabolic disease. Comparable to Mwyngil as a peer-stage metabolic disease biotech with overlapping patient populations.
• Madrigal Pharmaceuticals: Commercial-stage biopharmaceutical company with resmetirion for NASH/MASH, targeting inflammation-driven metabolic liver disease. Comparable to Mwyngil as a metabolic disease small-molecule developer.
• Terns Pharmaceuticals: Clinical-stage biopharmaceutical company developing oral small molecules (TERN-501, TERN-101) for obesity and NASH/MASH. Comparable as a metabolic disease-focused small-molecule developer targeting overlapping indications with Mwyngil.
• Olatec Therapeutics: Private clinical-stage biopharmaceutical company developing NLRP3 inflammasome inhibitors (dapansutrile and follow-on candidates) for inflammatory and metabolic diseases. Directly comparable to Mwyngil's MW-504/MW-313/BT-409 NLRP3 portfolio.
• Viking Therapeutics: Clinical-stage biopharmaceutical company developing oral and injectable small molecules (including VK2735 and VK2809) for obesity and metabolic disease. Closely comparable as a peer-stage metabolic small-molecule developer with multiple obesity programs.
• Sagimet Biosciences: Clinical-stage biopharmaceutical company developing FASN inhibitors (denifanstat) for NASH/MASH and potentially obesity. Comparable as a small-molecule developer addressing inflammation-driven metabolic liver disease.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Mwyngil
• LinkedInlinkedin.com/company/mwyngil

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mwyngil Therapeutics